Children's Hospital of Philadelphia leads or participates in hundreds of clinical research studies and clinical trials. Many of the studies that are currently enrolling patients can be found in this database. Use this finder to learn more about the purpose of these studies and clinical trials, find out who can participate, and tell us you're interested in enrolling. You can also look for studies that offer remote participation from home!
The ENERGY study is for adults (ages 18 and up) with warm Autoimmune Hemolytic Anemia (wAIHA) who are currently receiving treatment or have previously received treatment. The goal of the study is to see if the study drug, Nipocalimab is safe and effective in the treatment of wAIHA. Nipocalimab is an investigational medication designed to stop your immune system from destroying your red blood cells.
You may be able to join the study if you are:
Other study requirements will apply.
The purpose of this study is to see if a new topical (applied to the skin) formulation of rapamycin, PTX-022, is safe and effective in treating participants with microcystic Lymphatic Malformations (mLM).
This Phase 2 clinical research study is evaluating the safety and effectiveness of a once-daily oral investigational medicine that may improve anemia and reduce the need for red blood cell (RBC) transfusions among some patients who are chronically transfused. All participants enrolled in the study will receive the investigational medication.
We are currently enrolling individuals who meet the following criteria:*
Thalassemia and not receiving regular RBC transfusions (Cohort C)
There
are additional eligibility requirements, which the investigator will explain to
you.
The purpose of this research study is to test and adapt new techniques for performing magnetic resonance imaging (MRI). MRI provides pictures of the inside of the body and information about chemicals the body makes. Here are some examples of what we hope to accomplish:
1. Adapt MRI techniques used at other institutions for use on CHOP MRI scanners
2. Increase the amount of information learned from each MRI image
The research sequences involve changing the settings of the magnetic resonance scanner. By research sequences we mean that they are not approved by the US Food and Drug Administration (FDA) for clinical use. The data we obtain will help the FDA evaluate whether or not they can eventually approve the sequences for clinical use.
We are seeking to enroll healthy volunteers, 18 years of age and above. Pregnant females excluded for safety purposes.
The purpose of this study is to identify and engage young black or hispanic/latino men (male sex at birth, but gender identity male, transfemale, or gender nonconforming) (YBLMSM/transwomen) in Philadelphia, PA, Baltimore, MD and Washington, DC in HIV and substance use prevention using a new Mobile-enhanced Engagement intervention (app that reminds you to take your meds, reminds you of your medical appointments, etc.). There are three different parts to this study: 1) respondent driven sampling (RDS); 2) Randomized Control Trial (RCT): MEI vs Standard of Care for HIV+ youth; and 3) PrEP RCT: Pre Exposure Prophylaxis - Mobile-enhanced Engagement Intervention (PrEP-MEI) vs. Standard PrEP referral;. It is possible to participate in only the RDS, the RDS and the AIM 3 PrEP RCT, or the RDS and AIM 2 RCT studies.
The RDS study involves 2 study visits lasting up to 1 month of participation where participants will be asked to complete an optional rapid HIV test (oral or fingerstick) or viral load testing (blood draw), web-based survey (on past sexual and HIV experiences), recruit your peers to participate in the study, and complete a post-recruitment survey. YBLMSM/transwomen and cisgender females 15-24 years may participate in RDS, but the following study portions are only for YBLMSM/transwomen:
People who successfully complete the RDS portion of the study may be asked to participate in an additional study visit of an audio-recorded focus group or interview.
The RCT study involves 6 study visits (5 in person, 1 phone) and lasts 18 months. Participants will be assigned to one of two groups receiving different HIV supportive interventions: 1) HIV case management with a Mobile-enhanced Engagement Intervention (MEI), or 2) standard of care HIV case management where a case manager will remind you of medical appointments. If you are assigned to the first group (MEI), you will be asked to use the MEI mobile app or web-browser version of the app during the study period. Participants will be asked to complete a web-survey (on past sexual and HIV experiences), HIV Antibody and Viral load testing (blood draw), urine drug testing, and allow the researchers to access your medical charts for HIV and STI testing results. You may also be asked to participate in audio-recorded in-depth interviews.
The PrEP RCT study involves 5 study visits (5 in person, 1 phone) and lasts 18 months. Participants will be assigned to one of two groups receiving different PrEP and substance use supportive interventions: 1) PrEP case management with a Mobile-enhanced Engagement Intervention (MEI-PrEP), or 2) standard PrEP referrals to services. If you are assigned to the first group (MEI-PrEP), you will be asked to use the MEI-PrEP mobile app or web-browser version of the app during the study period. Participants will be asked to complete a web-survey (on past sexual and HIV experiences), HIV Antibody (blood draw or 2 rapid OraQuick tests in place of serologic 4th generation testing when 4th generation testing is not available) and Viral load testing (blood draw), urine drug testing, use the MEI-PrEP mobile app or web-browser version of the app, and allow the researchers to access your medical charts for HIV and STI testing results. You may also be asked to participate in audio-recorded in-depth interviews.
We are currently enrolling adolescents ages 15-21 of South Asian ancestry, African American ancestry, and European American or "White" ancestry. This study is looking to better understand ancestry related differences in risks for developing cardiovascular disease and type 2 diabetes. The study involves 2 visits to the CHOP Main Hospital in Philadelphia, and participants will be compensated for their efforts.
The purpose of this registry is to study the long-term effects and safety of Abatacept(Orencia) as used for the treatment of Juvenile Idiopathic Arthritis(JIA). JIA patients that are currently taking Abatacept may be eligible to participate in this study.
The purpose of this study is to assess deficits in movement and coordination in children with cerebral palsy (CP) and without. Children with CP have trouble coordinating their muscles while moving. Few options exist to measure muscle control. This new test will measure muscle control in children with and without CP and help guide future treatment plans.
Are you interested learning about opportunities to participate in research? Sign up to receive information about new research studies at CHOP. It’s a great way to support the work of the Research Institute.